Life After the Pill: Real-World Quality of Life Across CML Drugs and Treatment-Free Remission

Chronic myeloid leukemia was once a death sentence, but the arrival of tyrosine kinase inhibitors in the early 2000s transformed it into a manageable chronic condition with near-normal life expectancy. Yet as patients live for decades on daily medication, a new question has moved to the center of clinical care: not whether the disease is controlled, but how people actually feel while taking these drugs, or after stopping them altogether. A nationwide cross-sectional survey from Israel, published in Annals of Hematology, now offers one of the most detailed real-world pictures to date of health-related quality of life across the full spectrum of modern CML treatment, including the newest drug in the arsenal, asciminib, and the growing population of patients in treatment-free remission.

The study, led by Shira Buchrits and colleagues at the Institute of Hematology at the Davidoff Cancer Center, Rabin Medical Center, in collaboration with the Israeli CML Patients’ Organization, recruited 233 adults with CML. To be eligible, participants had to have received tyrosine kinase inhibitor therapy for at least three months, or to have discontinued therapy at least three months before taking part. Each participant completed validated Hebrew versions of two widely used patient-reported outcome instruments: the EORTC QLQ-C30, a general cancer quality-of-life questionnaire, and the QLQ-CML24, a disease-specific module designed to capture the symptoms and concerns unique to living with CML and its treatment.

The researchers divided participants into clinically meaningful groups reflecting the current therapeutic landscape: patients in treatment-free remission, those on first-generation TKIs such as imatinib, those on second-generation TKIs such as dasatinib and nilotinib, those on third-generation agents, and those receiving asciminib, a newer molecule that targets a distinct pocket of the BCR-ABL fusion protein. This grouping matters because the drugs differ substantially in their side-effect profiles. First-generation imatinib is associated with fluid retention, muscle cramps, and gastrointestinal upset; second-generation agents can produce fatigue, cardiovascular events, and metabolic changes; asciminib was designed with improved selectivity in the hope of reducing off-target toxicity.

The headline finding is reassuring: global health-related quality of life was generally preserved across all treatment groups. In other words, most people living with CML in Israel report an overall quality of life that remains intact regardless of which TKI they take or whether they have stopped treatment entirely. Treatment satisfaction and social functioning also remained high across the cohort, suggesting that the day-to-day social and practical lives of patients are largely unaffected by their treatment status. This is a striking testament to how far CML care has come since the pre-TKI era, when the disease carried a median survival of only a few years.

Beneath that reassuring surface, however, the survey revealed clinically meaningful differences in symptom burden between groups. Patients receiving second-generation TKIs reported a greater symptom burden in selected domains, including fatigue and gastrointestinal symptoms, compared with patients in treatment-free remission and those in other treatment groups. Mood disturbance also differed significantly across treatment groups, with numerically higher scores among patients taking second-generation agents. These are not trivial complaints. Fatigue in particular is one of the most commonly reported and most disabling symptoms among CML patients on long-term therapy, and it can erode work capacity, exercise tolerance, and social participation even when blood counts are perfectly controlled.

At the opposite end of the spectrum stood two groups: patients in treatment-free remission and those receiving asciminib. Both consistently reported lower symptom burden and more favorable quality-of-life profiles. For patients in treatment-free remission, the finding is intuitive but important to document. Treatment-free remission, in which patients with sustained deep molecular response stop their TKI under close molecular monitoring, has become an achievable goal for a substantial minority of patients since large stopping studies demonstrated its feasibility. The new data confirm that successful discontinuation is associated with a real and measurable improvement in how patients feel, not merely with freedom from the cost and inconvenience of daily pills.

The favorable profile of asciminib is perhaps the more novel observation. Asciminib works through allosteric binding to the myristoyl pocket of the BCR-ABL kinase, a mechanism distinct from the ATP-binding site targeted by all earlier TKIs. This selectivity was expected to translate into fewer off-target effects, and the new survey provides patient-reported evidence consistent with that expectation in a real-world setting. Because asciminib is often prescribed precisely for patients who have experienced intolerance or resistance to earlier agents, the fact that these patients report low symptom burden is notable, although the cross-sectional design means that differences in who receives which drug could influence the comparison.

That caveat points to the broader interpretive limits of the study. As a cross-sectional survey, it captures a snapshot rather than a trajectory, and patients are not randomized to treatment groups. Patients on later-generation drugs may have more resistant disease or more prior toxicity, which could color their self-reported experience. Nevertheless, the nationwide scope of the survey, its partnership with the national patient organization, and its use of validated instruments in the patients’ native language give the findings a credibility that smaller, single-center studies often lack. The study was approved by the Institutional Review Board of Rabin Medical Center and conducted in accordance with the Declaration of Helsinki.

The clinical implications are straightforward. As the authors emphasize, the results underscore the importance of integrating patient-reported outcomes into individualized therapeutic decision-making in modern CML care. With several TKIs now available, each with comparable efficacy in many settings, the choice among them increasingly hinges on tolerability, comorbidities, and patient preference. Systematic collection of patient-reported outcomes can make those conversations concrete, revealing fatigue, gastrointestinal symptoms, or mood disturbance that might otherwise go unmentioned in a brief clinic visit focused on molecular response levels.

For patients, the message is equally clear. Living well with CML is now the norm, not the exception, and feeling unwell on treatment should prompt a conversation rather than quiet endurance. Whether through switching to a better-tolerated agent such as asciminib, or through a carefully monitored attempt at treatment-free remission for those with deep sustained responses, the therapeutic toolkit now offers multiple paths to not only controlling the leukemia but also minimizing its footprint on daily life. This study adds real-world, patient-voiced evidence that those paths lead to measurably different experiences, and that the goal of CML medicine has genuinely moved beyond disease control.

Subject of Research: Health-related quality of life across tyrosine kinase inhibitors and treatment-free remission in chronic myeloid leukemia

Article Title: Beyond disease control in chronic myeloid leukemia: Real-world quality of life across TKIs and treatment-free remission

Article References: Buchrits, S., Sharf, G., Raanani, P., & Abulafia, A. S. (2026). Beyond disease control in chronic myeloid leukemia: Real-world quality of life across TKIs and treatment-free remission. Annals of Hematology. https://doi.org/10.1007/s00277-026-07298-1

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07298-1

Keywords: chronic myeloid leukemia, tyrosine kinase inhibitors, quality of life, patient-reported outcomes, treatment-free remission, asciminib, fatigue, EORTC QLQ-C30, QLQ-CML24, hematology, drug tolerability, molecular response